Dexamethasone for the Prevention of Cisplatin-induced Ototoxicity

Popay, Ashley R. and Lloyd, Daniel R. and Wass, Mark N. and Michaelis, Martin (2017) Dexamethasone for the Prevention of Cisplatin-induced Ototoxicity. Clinical Cancer Drugs, 4 (1). pp. 59-64. ISSN 2212-697X. E-ISSN 2212-6988. (doi:https://doi.org/10.2174/2212697X04666170331171359) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)
Official URL
https://doi.org/10.2174/2212697X04666170331171359

Abstract

Background: Cisplatin is a commonly used anti-cancer drug. However, its use is associated with severe side effects including ototoxicity that affects a large fraction of cisplatin-treated patients. Approved therapies that reduce cisplatin-induced ototoxicity are lacking. Among the candidate therapeutics, dexamethasone stands out. There is extensive experience of its use in combination with cisplatin for the prevention of chemotherapy-induced nausea and vomiting indicating that dexamethasone does not affect the anti-cancer effects of cisplatin. Objective: The objective of this study is to assess the potential of dexamethasone for the prevention of cisplatin-induced ototoxicity by a systematic analysis of the available evidence. Method: The databases PubMed and Web of Science were used to identify relevant articles by using the search terms 'cisplatin', 'ototoxicity', and 'dexamethasone'. Results: We identified 16 relevant original research articles. The analyzed studies reported conflicting results on the effects of dexamethasone on cisplatin-induced ototoxicity. However, studies in which dexamethasone was used prior to cisplatin treatment and directly administered into the tympanic cavity of the middle ear consistently reported beneficial effects. The use of sustained release formulations that prolong the availability of dexamethasone within the ear further improved the efficacy of dexamethasone. Conclusion: Dexamethasone is a promising candidate drug for the prevention of cisplatin-induced ototoxicity when applied intratympanically. Optimized formulations and administration schedules with regard to dose and time of application need to be developed.

Item Type: Article
Uncontrolled keywords: Cisplatin, ototoxicity, dexamethasone, cancer, chemotherapy, side effects, adverse events.
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 12 Jun 2017 16:50 UTC
Last Modified: 13 Jun 2017 08:08 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/62045 (The current URI for this page, for reference purposes)
Wass, Mark N.: https://orcid.org/0000-0001-5428-6479
Michaelis, Martin: https://orcid.org/0000-0002-5710-5888
  • Depositors only (login required):